[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626918":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":43,"centralContacts":47,"locations":56,"responsibleParty":194,"collaborators":28,"id":196,"slug":197,"hasResults":198,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":198,"sex":204,"minAge":205,"maxAge":206,"enrollmentInfo":207,"targetDuration":28,"studyType":210,"phases":211,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":59,"whyStopped":28,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":236},{"fullName":5,"class":6},"BioMarin Pharmaceutical","INDUSTRY",[8,14,17,20,26,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 2: Low Dose","EXPERIMENTAL","Participants will be randomized to receive different dose levels of BMN 333",[13],"Drug: BMN 333",{"label":15,"type":10,"description":11,"interventionNames":16},"Phase 2: Medium Dose",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Phase 2: High Dose",[13],{"label":21,"type":22,"description":23,"interventionNames":24},"Phase 2: Vosoritide","ACTIVE_COMPARATOR","weight band dosing, Modified recombinant human C-type natriuretic peptide Vosoritide",[25],"Drug: Vosoritide Injection [Voxzogo]",{"label":27,"type":10,"description":28,"interventionNames":29},"Phase 3: BMN 333 at selected dose after Phase 2",null,[13],{"label":31,"type":22,"description":23,"interventionNames":32},"Phase 3: Vosoritide",[25],[34,39],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":28},"DRUG","BMN 333","Administration: Weekly subcutaneous injection",[18,9,15,27],{"type":35,"name":40,"description":41,"armGroupLabels":42,"otherNames":28},"Vosoritide Injection [Voxzogo]","Administration: Daily subcutaneous injection",[21,31],[44],{"name":45,"affiliation":5,"role":46},"Medical Director, PhD","STUDY_DIRECTOR",[48,53],{"name":49,"role":50,"phone":51,"phoneExt":28,"email":52},"Trial Specialist","CONTACT","1-800-983-4587","medinfo@bmrn.com",{"name":54,"role":50,"phone":51,"phoneExt":28,"email":55},"Study Manager","Medinfo@bmrn.com",[57,74,88,101,114,126,141,155,169,181],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"UCSF Benioff Children's Hospital Oakland","RECRUITING","Oakland","California","94609","United States","US",{"type":66,"coordinates":67},"Point",[68,69],-122.2708,37.80437,{"lat":69,"lon":68},[72],{"name":73,"role":50,"phone":28,"phoneExt":28,"email":28},"Hind Al-Saif",{"facility":75,"status":76,"city":77,"state":78,"zip":79,"country":63,"countryCode":64,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Ann & Robert H. Lurie Children's Hospital of Chicago","NOT_YET_RECRUITING","Chicago","Illinois","60611",{"type":66,"coordinates":81},[82,83],-87.65005,41.85003,{"lat":83,"lon":82},[86],{"name":87,"role":50,"phone":28,"phoneExt":28,"email":28},"Carlos Prada",{"facility":89,"status":76,"city":90,"state":91,"zip":92,"country":63,"countryCode":64,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Johns Hopkins Medicine Julie","Baltimore","Maryland","21205",{"type":66,"coordinates":94},[95,96],-76.61219,39.29038,{"lat":96,"lon":95},[99],{"name":100,"role":50,"phone":28,"phoneExt":28,"email":28},"Julie Hoover-Fong",{"facility":102,"status":59,"city":103,"state":104,"zip":105,"country":63,"countryCode":64,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Texas Children Hospital, Baylor College of Medicine, Houston TX","Houston","Texas","77030",{"type":66,"coordinates":107},[108,109],-95.36327,29.76328,{"lat":109,"lon":108},[112],{"name":113,"role":50,"phone":28,"phoneExt":28,"email":28},"Carlos Bacino",{"facility":115,"status":59,"city":116,"state":104,"zip":117,"country":63,"countryCode":64,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Consano Clinical Research, LLC","San Antonio","78231",{"type":66,"coordinates":119},[120,121],-98.49363,29.42412,{"lat":121,"lon":120},[124],{"name":125,"role":50,"phone":28,"phoneExt":28,"email":28},"Daniel Katselnik",{"facility":127,"status":59,"city":128,"state":129,"zip":130,"country":131,"countryCode":132,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Murdoch Children's Research Institute","Parkville","Victoria","3052","Australia","AU",{"type":66,"coordinates":134},[135,136],144.95,-37.78333,{"lat":136,"lon":135},[139],{"name":140,"role":50,"phone":28,"phoneExt":28,"email":28},"Ravi Savarirayan",{"facility":142,"status":76,"city":143,"state":28,"zip":144,"country":145,"countryCode":146,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Irccs Ospedale Gaslini Di Genova","Genova","16147","Italy","IT",{"type":66,"coordinates":148},[149,150],11.87211,45.21604,{"lat":150,"lon":149},[153],{"name":154,"role":50,"phone":28,"phoneExt":28,"email":28},"Mohamed Maghnie",{"facility":156,"status":76,"city":157,"state":28,"zip":158,"country":159,"countryCode":160,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Craiova Emergency Clinical County","Craiova","200642","Romania","RO",{"type":66,"coordinates":162},[163,164],23.8,44.31667,{"lat":164,"lon":163},[167],{"name":168,"role":50,"phone":28,"phoneExt":28,"email":28},"Ioana Streata",{"facility":170,"status":76,"city":171,"state":28,"zip":28,"country":172,"countryCode":28,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"Seoul National University Hospital","Seoul","South Korea",{"type":66,"coordinates":174},[175,176],126.9784,37.566,{"lat":176,"lon":175},[179],{"name":180,"role":50,"phone":28,"phoneExt":28,"email":28},"Jung Min Ko",{"facility":182,"status":76,"city":183,"state":28,"zip":28,"country":184,"countryCode":185,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"University Hospitals Bristol NHS Foundation Trust - Bristol Royal Hospital for Children","Bristol","United Kingdom","UK",{"type":66,"coordinates":187},[188,189],-2.59665,51.45523,{"lat":189,"lon":188},[192],{"name":193,"role":50,"phone":28,"phoneExt":28,"email":28},"Toby Candler",{"type":195,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100626918","phase-2-study-to-evaluate-the-efficacy-and-safety-of-bmn-333-versus-vosoritide-in-children-with-achondroplasia-100626918",false,"NCT07441876","Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia","A Multicenter, Randomized, Operationally Seamless Phase 2\u002F3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia","ASPEN","Inclusion Criteria:\n\n1. Participants must be aged ≥ 2 to \\\u003C 11 years (Phase 2) or ≥ 2 to \\\u003C 18 years (Phase 3), at the time of signing the informed consent\n2. Participants must have ACH (confirmed by documented genetic testing) and open epiphyses\n3. Are Tanner Stage I (Phase 2) or any Tanner stage (Phase 3)\n4. Are ambulatory and able to stand without assistance\n\nExclusion Criteria:\n\n1. Have any short stature condition other than ACH (eg, hypochondroplasia, trisomy 21, pseudoachondroplasia, GH deficiency)\n2. Have any of the following disorders: Hypothyroidism or hyperthyroidism, unless treated with evidence of normalized thyroid-stimulating hormone (TSH) levels, diabetes mellitus, unless considered well-controlled, autoimmune inflammatory disease, inflammatory bowel disease, autonomic neuropathy, anemia defined as hemoglobin \\\u003C 10 g\u002FdL, vitamin D deficiency, significant hip pathology.\n3. Have history of any renal insufficiency or cardiac\u002F cardiovascular disease that places the participant at increased risk of an adverse cardiac outcome in the setting of hypotension.\n4. Have had bone fractures of the long bones or spine within 6 months prior to screening.\n5. Have used vosoritide, any other approved product (except GH, as detailed below), investigational product, or investigational medical device for the treatment of ACH or short stature at any time\n6. Have been treated with GH, insulin-like growth factor 1, or anabolic steroids in the 6 months prior to treatment start","ALL","2 Years","17 Years",{"count":208,"type":209},160,"ESTIMATED","INTERVENTIONAL",[212,213],"PHASE2","PHASE3","This is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2\u002F3 study of BMN 333 in treatment-naïve pediatric participants with achondroplasia (ACH). The study consists of a Phase 2 part and a Phase 3 part.",[216],"Achondroplasia",[216,218,219,220,221,222,223,224,225,226],"ACH","Bone Diseases, Developmental Dwarfism","Bone Diseases","Genetic Diseases, Inborn","Musculoskeletal Diseases","Natriuretic Peptide, C-type","Osteochondrodysplasias","Physiological Effects of Drugs","Skeletal Dysplasias","2026-05-27",{"date":229,"type":230},"2026-05-29","ACTUAL",{"date":232,"type":209},"2026-04",{"date":234,"type":209},"2029-09",{"name":5,"class":6},10]